Uses of NOGO-A inhibitors and related methods

• US 8,828,390 B2
• Filed: 07/08/2011
• Issued: 09/09/2014
• Est. Priority Date: 07/09/2010
• Status: Active Grant

• Current Assignee: Universite de Geneve
• Original Assignee: Universität Zürich, Universite de Geneve
• Inventors: Herrera, Pedro L., Schwab, Martin E., Bonal, Claire, Lalive D'epinay, Patrice, Pot Kreis, Caroline
• Primary Examiner(s): Shafer, Shulamith H
• Application Number:
  US13/809,224
• Publication Number:
  US 20130136737A1
• Time in Patent Office: 1,159 Days
• US Class Current: 424/141.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/0005 Vertebrate antigens from snakes A61K39/38
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.

Claims

1. A method of controlling blood glucose or blood insulin levels in a subject, said method comprising administering to a subject in need thereof an insulin secretory effective amount of a neutralising monoclonal anti-Nogo-A antibody, or a pharmaceutical formulation thereof.

2. The method according to claim 1, wherein the subject is suffering from insulin resistance.

3. The method according to claim 1, wherein the subject is suffering from diabetes mellitus.

4. The method according to claim 3, wherein diabetes mellitus is type II diabetes.

5. The method according claim 1, wherein the neutralising monoclonal anti-Nogo-A antibody is a neutralising monoclonal anti-Nogo-A antibody selected from humanised variants of mAbs 11C7, 2A10 or 2C4;

and mAbs 6A3, H20L16, H27L16, H28L13 and H28L16.

6. The method according to claim 1, wherein the neutralising monoclonal anti-Nogo-A antibody is a humanised variant of mAb 11C7.

7. A method of repressing or treating insulin secretion deficiency in a subject, said method comprising administering in a subject in need thereof a therapeutically effective amount of a neutralising monoclonal anti-Nogo-A antibody, or a pharmaceutical formulation thereof.

8. The method according to claim 7, wherein the neutralising monoclonal anti-Nogo-A antibody is a neutralising anti-Nogo-A antibody selected from humanised variants of mAbs 11C7, 2A10 or 2C4;

and mAbs 6A3, H20L16, H27L16, H28L13 and H28L16.

9. The method according to claim 7, wherein the neutralising monoclonal anti-Nogo-A antibody is a humanised variant of mAb 11C7 neutralising anti-Nogo-A antibody.

10. A pharmaceutical formulation comprising a neutralizing monoclonal anti-Nogo-A antibody, combined with at least one co-agent useful in the stimulation of insulin secretion or in the treatment of diabetes mellitus, and at least one pharmaceutically acceptable carrier.

11. The pharmaceutical formulation according to claim 10, wherein the neutralising monoclonal anti-Nogo-A antibody is a neutralising monoclonal anti-Nogo-A antibody selected from humanised variants of mAbs 11C7, 2A10 or 2C4;

and mAbs 6A3, H20L16, H27L16, H28L13 and H28L16.

12. The pharmaceutical formulation according to claim 10, wherein the neutralising monoclonal anti-Nogo-A antibody is a humanised variant of mAb 11C7 neutralising monoclonal anti-Nogo-A antibody.